Cochlear Limited (ASX: COH) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Cochlear Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Cochlear Limited (ASX: COH)
Latest News
Technology Shares
Why the healthcare sector could outperform ASX tech stocks in 2020
⏸️ ASX Shares
Where to invest your Rio Tinto dividends today
Share Market News
5 things to watch on the ASX 200 on Thursday
Resources Shares
3 ASX large cap stocks I like for the next decade
Healthcare Shares
Is the CSL share price still a buy?
Growth Shares
Why I would buy and hold Nanosonics and these quality ASX shares
⏸️ ASX Shares
Why I would buy these blue chip ASX 200 shares today
Share Market News
Why the Nanosonics and ResMed share prices are hitting record highs this week
Share Market News
3 books to help build serious wealth on the ASX
⏸️ Dividend Shares
Is WiseTech Global a buy for its dividend?
⏸️ Growth Investing
3 ASX50 growth stocks for a stress-free life
Share Market News
Goldman Sachs is unimpressed by Cochlear management's "bullish" commentary
Frequently Asked Questions
-
Yes, Cochlear Ltd has historically paid two fully franked dividends a year.
-
Cochlear Ltd generally pays its dividends in April and October.
-
Cochlear Ltd listed on the ASX on 4 December 1995.
COH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Cochlear Limited
Cochlear Ltd (ASX: COH) is the world's leading cochlear implant device manufacturer with around half of global market share.
The company was founded in Australia in 1983 to commercialise implants pioneered by Melbourne researcher Dr Graeme Clark, but later became a separate entity.
Developed markets contribute the bulk of Cochlear's group revenue with cochlear implants the standard of care for children with severe to profound hearing loss. The company is also catering for a growing cohort of seniors when standard hearing aid technology loses its effectiveness.
Cochlear's main products include cochlear implants, bone-anchored hearing devices, and associated sound processors. The vast majority of Cochlear's revenue is derived from overseas, with the US and Europe by far the company's two largest markets.
